Clinical Trial

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and efficacy of interleukin-7(IL-7) / interleukin-15 (IL-15) manufactured CAR T cells in adult patients with relapsed and/or refractory myeloma that have failed prior therapies.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-11
Trial Details
NCT Number NCT05976555
Lead Sponsor Medical College of Wisconsin
Conditions Multiple Myeloma
Enrollment 30 participants
Start Date 2026-05-15
Primary Completion 2028-05 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-10